Clinical Trial Update: A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years. [Phase 3]

View source ↗

Summary

Phase 3 results report on safety, tolerability, and immunogenicity of the bivalent rLP2086 meningococcal vaccine in healthy adults aged 18 to under 26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Trumenba (rLP2086)

Snippet

Sponsor: Pfizer | Conditions: Healthy | Phase 3 | Status: COMPLETED | Results posted: 2016-02-23